KLK3 and prostate carcinoma: Observations made from the European Randomized Study of Screening for Prostate Cancer (ERSPC), indicated that PSA screening contributed to a substantial (~ 21%) decrease in PCa mortality after 13 years follow up of non-screened and screened men [33].